Rinvoq
E697098
Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Rinvoq canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T7930813 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Rinvoq Context triple: [AbbVie, notableProduct, Rinvoq]
-
A.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Rinvoq Target entity description: Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
-
A.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
-
B.
Anpezan
Anpezan is a regional dialect of the Ladin language spoken in parts of the Dolomite area of northern Italy.
-
C.
Darzalex
Darzalex is a monoclonal antibody drug (daratumumab) used primarily in the treatment of multiple myeloma.
-
D.
Donepezil
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
-
E.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
- F. None of above. chosen
Statements (53)
| Predicate | Object |
|---|---|
| instanceOf |
Janus kinase inhibitor
ⓘ
brand name drug ⓘ pharmaceutical drug ⓘ small molecule drug ⓘ |
| approvalAgency |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| ATCCode | L04AA44 ⓘ |
| commonAdverseEffect |
acne
ⓘ
cough ⓘ elevated cholesterol ⓘ elevated liver enzymes ⓘ fever ⓘ nausea ⓘ upper respiratory tract infection ⓘ |
| contraindication |
known hypersensitivity to upadacitinib
ⓘ
severe hepatic impairment ⓘ |
| countryOfFirstApproval | United States NERFINISHED ⓘ |
| developedBy | AbbVie NERFINISHED ⓘ |
| dosageForm | extended-release tablet ⓘ |
| firstApprovalYear | 2019 ⓘ |
| hasActiveIngredient | upadacitinib ⓘ |
| hasBlackBoxWarning |
major adverse cardiovascular events
ⓘ
malignancy ⓘ serious infections ⓘ thrombosis ⓘ |
| indication |
Crohn's disease
ⓘ
ankylosing spondylitis ⓘ atopic dermatitis ⓘ juvenile psoriatic arthritis ⓘ non-radiographic axial spondyloarthritis ⓘ polyarticular juvenile idiopathic arthritis ⓘ psoriatic arthritis ⓘ rheumatoid arthritis ⓘ ulcerative colitis ⓘ |
| intendedUse | treatment of inflammatory and autoimmune diseases ⓘ |
| legalStatusInEU | prescription only ⓘ |
| legalStatusInUS | prescription only ⓘ |
| manufacturer | AbbVie NERFINISHED ⓘ |
| mechanismOfAction | selective inhibition of JAK1 ⓘ |
| pharmacologicalClass | JAK inhibitor ⓘ |
| pregnancyCategory | may cause fetal harm (risk-based warning) ⓘ |
| regulatoryStatus | prescription only ⓘ |
| routeOfAdministration | oral ⓘ |
| targets | Janus kinase 1 NERFINISHED ⓘ |
| treats |
active ankylosing spondylitis
ⓘ
active juvenile psoriatic arthritis ⓘ active non-radiographic axial spondyloarthritis ⓘ active polyarticular juvenile idiopathic arthritis ⓘ active psoriatic arthritis ⓘ moderate to severe Crohn's disease ⓘ moderate to severe atopic dermatitis ⓘ moderate to severe rheumatoid arthritis ⓘ moderate to severe ulcerative colitis ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Rinvoq Description of subject: Rinvoq is a prescription JAK inhibitor medication used to treat various inflammatory and autoimmune conditions such as rheumatoid arthritis and atopic dermatitis.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.